General Info

La Jolla Pharmaceutical Company is a biotechnology company engaged in the development of therapeutics for antibody-mediated autoimmune diseases afflicting several million people in the United States and Europe. The company is developing riquent for the treatment of patients with lupus kidney disease, a leading cause of sickness and death in lupus patients. The company is also developing small molecules to treat various other autoimmune and inflammatory conditions. The company's common stock is traded on the Nasdaq Stock Market under the symbol LJPC. La Jolla Pharmaceutical Company is headquartered in San Diego.